quantiferon gold in-tube (Cellestis limited)
90
Structured Review
Cellestis limited
quantiferon gold in-tube
Quantiferon Gold In Tube, supplied by Cellestis limited, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/quantiferon%C2%AE-tb+gold+tube/quantiferon+tb+gold/pm38166111-32-25-27
Average 90 stars, based on 1 article reviews
Quantiferon Gold In Tube, supplied by Cellestis limited, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/quantiferon%C2%AE-tb+gold+tube/quantiferon+tb+gold/pm38166111-32-25-27
Average 90 stars, based on 1 article reviews
quantiferon gold in-tube - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Adjuvant:Article Title: Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis. Article Snippet: IGRA includes QFT-G, Article Title: Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm 3 : A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial Article Snippet: Number of subjects 48 Country South Africa and Tanzania Investigational product H1/IC31 ® Dosage H1 antigen: 50 μg IC31 adjuvant: 500 nmol KLK and 20 nmol ODN1a Dosage volume 0.5 ml Administration Two intramuscular injections, one on day 0 and one on day 56 Aurum 102 / THYB-05 The Aurum Institute and Statens Serum Institut Version 2.1 Page 4 of 48 15 February 2011 List of abbreviations GT Gamma glutamyl-transpeptidase AE Adverse event(s) Ag85B Antigen 85B AIDS Acquired Immune Deficiency Syndrome ALAT Alanine aminotransferase AM Abbreviated medical examination Aurum The Aurum Institute BCG Bacillus Calmette-Guérin CBC Complete blood count CFSE Carboxyfluorescein diacetate succinimidyl ester CPK Creatine phosphokinase CPT Cell Preparation Tube CRF Case Report Form(s) CTA Clinical Trials Application DAIDS National Institute of Health Division of AIDS DSMB Data Safety Monitoring Board EC Ethics Committee ELISA Enzyme Linked Immunosorbent Assay ELISPOT Enzyme Linked Immunosorbent Spot Assay ESAT-6 Early Secretory Antigenic Target FDA United States Food and Drug Administration FM Full medical examination FU Follow up GCP Good clinical practice(s) H1 Hybrid 1 (Ag85B-ESAT-6) H1/IC31® Ag85B-ESAT-6 + IC31 HBV Hepatitis B virus HCV Hepatitis C virus HIV Human immunodeficiency virus IB Investigator’s Brochure IC31 KLK, ODN1a ICH International Conference on Harmonisation ICS Intracellular Cytokine Staining IFNγ Interferon-gamma IgG Immunoglobulin G IgM Immunoglobulin M IM Intramuscular IRB Institutional Review Board KLK KLKLLLLLKLK LUMC Leiden University Medical Center MCC Medicines Control Council (South Africa) mL Milliliter(s) Mtb Mycobacterium tuberculosis Aurum 102 / THYB-05 The Aurum Institute and Statens Serum Institut Version 2.1 Page 5 of 48 15 February 2011 ODN1a Oligodeoxynucleotide PBMC Peripheral blood mononuclear cell(s) PCR Polymerase chain reaction PHA phytohemagglutinin PPD Purified protein derivative pys patient years QFT-GIT QuantiFERON®-TB Gold In Enzyme-linked Immunosorbent Assay:Article Title: Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis. Article Snippet: IGRA includes QFT-G, Article Title: Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm 3 : A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial Article Snippet: Number of subjects 48 Country South Africa and Tanzania Investigational product H1/IC31 ® Dosage H1 antigen: 50 μg IC31 adjuvant: 500 nmol KLK and 20 nmol ODN1a Dosage volume 0.5 ml Administration Two intramuscular injections, one on day 0 and one on day 56 Aurum 102 / THYB-05 The Aurum Institute and Statens Serum Institut Version 2.1 Page 4 of 48 15 February 2011 List of abbreviations GT Gamma glutamyl-transpeptidase AE Adverse event(s) Ag85B Antigen 85B AIDS Acquired Immune Deficiency Syndrome ALAT Alanine aminotransferase AM Abbreviated medical examination Aurum The Aurum Institute BCG Bacillus Calmette-Guérin CBC Complete blood count CFSE Carboxyfluorescein diacetate succinimidyl ester CPK Creatine phosphokinase CPT Cell Preparation Tube CRF Case Report Form(s) CTA Clinical Trials Application DAIDS National Institute of Health Division of AIDS DSMB Data Safety Monitoring Board EC Ethics Committee ELISA Enzyme Linked Immunosorbent Assay ELISPOT Enzyme Linked Immunosorbent Spot Assay ESAT-6 Early Secretory Antigenic Target FDA United States Food and Drug Administration FM Full medical examination FU Follow up GCP Good clinical practice(s) H1 Hybrid 1 (Ag85B-ESAT-6) H1/IC31® Ag85B-ESAT-6 + IC31 HBV Hepatitis B virus HCV Hepatitis C virus HIV Human immunodeficiency virus IB Investigator’s Brochure IC31 KLK, ODN1a ICH International Conference on Harmonisation ICS Intracellular Cytokine Staining IFNγ Interferon-gamma IgG Immunoglobulin G IgM Immunoglobulin M IM Intramuscular IRB Institutional Review Board KLK KLKLLLLLKLK LUMC Leiden University Medical Center MCC Medicines Control Council (South Africa) mL Milliliter(s) Mtb Mycobacterium tuberculosis Aurum 102 / THYB-05 The Aurum Institute and Statens Serum Institut Version 2.1 Page 5 of 48 15 February 2011 ODN1a Oligodeoxynucleotide PBMC Peripheral blood mononuclear cell(s) PCR Polymerase chain reaction PHA phytohemagglutinin PPD Purified protein derivative pys patient years QFT-GIT QuantiFERON®-TB Gold In Enzyme-linked Immunospot:Article Title: Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis. Article Snippet: IGRA includes QFT-G, Article Title: Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm 3 : A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial Article Snippet: Number of subjects 48 Country South Africa and Tanzania Investigational product H1/IC31 ® Dosage H1 antigen: 50 μg IC31 adjuvant: 500 nmol KLK and 20 nmol ODN1a Dosage volume 0.5 ml Administration Two intramuscular injections, one on day 0 and one on day 56 Aurum 102 / THYB-05 The Aurum Institute and Statens Serum Institut Version 2.1 Page 4 of 48 15 February 2011 List of abbreviations GT Gamma glutamyl-transpeptidase AE Adverse event(s) Ag85B Antigen 85B AIDS Acquired Immune Deficiency Syndrome ALAT Alanine aminotransferase AM Abbreviated medical examination Aurum The Aurum Institute BCG Bacillus Calmette-Guérin CBC Complete blood count CFSE Carboxyfluorescein diacetate succinimidyl ester CPK Creatine phosphokinase CPT Cell Preparation Tube CRF Case Report Form(s) CTA Clinical Trials Application DAIDS National Institute of Health Division of AIDS DSMB Data Safety Monitoring Board EC Ethics Committee ELISA Enzyme Linked Immunosorbent Assay ELISPOT Enzyme Linked Immunosorbent Spot Assay ESAT-6 Early Secretory Antigenic Target FDA United States Food and Drug Administration FM Full medical examination FU Follow up GCP Good clinical practice(s) H1 Hybrid 1 (Ag85B-ESAT-6) H1/IC31® Ag85B-ESAT-6 + IC31 HBV Hepatitis B virus HCV Hepatitis C virus HIV Human immunodeficiency virus IB Investigator’s Brochure IC31 KLK, ODN1a ICH International Conference on Harmonisation ICS Intracellular Cytokine Staining IFNγ Interferon-gamma IgG Immunoglobulin G IgM Immunoglobulin M IM Intramuscular IRB Institutional Review Board KLK KLKLLLLLKLK LUMC Leiden University Medical Center MCC Medicines Control Council (South Africa) mL Milliliter(s) Mtb Mycobacterium tuberculosis Aurum 102 / THYB-05 The Aurum Institute and Statens Serum Institut Version 2.1 Page 5 of 48 15 February 2011 ODN1a Oligodeoxynucleotide PBMC Peripheral blood mononuclear cell(s) PCR Polymerase chain reaction PHA phytohemagglutinin PPD Purified protein derivative pys patient years QFT-GIT QuantiFERON®-TB Gold In ELISpot Assay:Article Title: Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis. Article Snippet: IGRA includes QFT-G, Article Title: Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm 3 : A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial Article Snippet: Number of subjects 48 Country South Africa and Tanzania Investigational product H1/IC31 ® Dosage H1 antigen: 50 μg IC31 adjuvant: 500 nmol KLK and 20 nmol ODN1a Dosage volume 0.5 ml Administration Two intramuscular injections, one on day 0 and one on day 56 Aurum 102 / THYB-05 The Aurum Institute and Statens Serum Institut Version 2.1 Page 4 of 48 15 February 2011 List of abbreviations GT Gamma glutamyl-transpeptidase AE Adverse event(s) Ag85B Antigen 85B AIDS Acquired Immune Deficiency Syndrome ALAT Alanine aminotransferase AM Abbreviated medical examination Aurum The Aurum Institute BCG Bacillus Calmette-Guérin CBC Complete blood count CFSE Carboxyfluorescein diacetate succinimidyl ester CPK Creatine phosphokinase CPT Cell Preparation Tube CRF Case Report Form(s) CTA Clinical Trials Application DAIDS National Institute of Health Division of AIDS DSMB Data Safety Monitoring Board EC Ethics Committee ELISA Enzyme Linked Immunosorbent Assay ELISPOT Enzyme Linked Immunosorbent Spot Assay ESAT-6 Early Secretory Antigenic Target FDA United States Food and Drug Administration FM Full medical examination FU Follow up GCP Good clinical practice(s) H1 Hybrid 1 (Ag85B-ESAT-6) H1/IC31® Ag85B-ESAT-6 + IC31 HBV Hepatitis B virus HCV Hepatitis C virus HIV Human immunodeficiency virus IB Investigator’s Brochure IC31 KLK, ODN1a ICH International Conference on Harmonisation ICS Intracellular Cytokine Staining IFNγ Interferon-gamma IgG Immunoglobulin G IgM Immunoglobulin M IM Intramuscular IRB Institutional Review Board KLK KLKLLLLLKLK LUMC Leiden University Medical Center MCC Medicines Control Council (South Africa) mL Milliliter(s) Mtb Mycobacterium tuberculosis Aurum 102 / THYB-05 The Aurum Institute and Statens Serum Institut Version 2.1 Page 5 of 48 15 February 2011 ODN1a Oligodeoxynucleotide PBMC Peripheral blood mononuclear cell(s) PCR Polymerase chain reaction PHA phytohemagglutinin PPD Purified protein derivative pys patient years QFT-GIT QuantiFERON®-TB Gold In Virus:Article Title: Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis. Article Snippet: IGRA includes QFT-G, Article Title: Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm 3 : A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial Article Snippet: Number of subjects 48 Country South Africa and Tanzania Investigational product H1/IC31 ® Dosage H1 antigen: 50 μg IC31 adjuvant: 500 nmol KLK and 20 nmol ODN1a Dosage volume 0.5 ml Administration Two intramuscular injections, one on day 0 and one on day 56 Aurum 102 / THYB-05 The Aurum Institute and Statens Serum Institut Version 2.1 Page 4 of 48 15 February 2011 List of abbreviations GT Gamma glutamyl-transpeptidase AE Adverse event(s) Ag85B Antigen 85B AIDS Acquired Immune Deficiency Syndrome ALAT Alanine aminotransferase AM Abbreviated medical examination Aurum The Aurum Institute BCG Bacillus Calmette-Guérin CBC Complete blood count CFSE Carboxyfluorescein diacetate succinimidyl ester CPK Creatine phosphokinase CPT Cell Preparation Tube CRF Case Report Form(s) CTA Clinical Trials Application DAIDS National Institute of Health Division of AIDS DSMB Data Safety Monitoring Board EC Ethics Committee ELISA Enzyme Linked Immunosorbent Assay ELISPOT Enzyme Linked Immunosorbent Spot Assay ESAT-6 Early Secretory Antigenic Target FDA United States Food and Drug Administration FM Full medical examination FU Follow up GCP Good clinical practice(s) H1 Hybrid 1 (Ag85B-ESAT-6) H1/IC31® Ag85B-ESAT-6 + IC31 HBV Hepatitis B virus HCV Hepatitis C virus HIV Human immunodeficiency virus IB Investigator’s Brochure IC31 KLK, ODN1a ICH International Conference on Harmonisation ICS Intracellular Cytokine Staining IFNγ Interferon-gamma IgG Immunoglobulin G IgM Immunoglobulin M IM Intramuscular IRB Institutional Review Board KLK KLKLLLLLKLK LUMC Leiden University Medical Center MCC Medicines Control Council (South Africa) mL Milliliter(s) Mtb Mycobacterium tuberculosis Aurum 102 / THYB-05 The Aurum Institute and Statens Serum Institut Version 2.1 Page 5 of 48 15 February 2011 ODN1a Oligodeoxynucleotide PBMC Peripheral blood mononuclear cell(s) PCR Polymerase chain reaction PHA phytohemagglutinin PPD Purified protein derivative pys patient years QFT-GIT QuantiFERON®-TB Gold In Staining:Article Title: Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis. Article Snippet: IGRA includes QFT-G, Article Title: Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm 3 : A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial Article Snippet: Number of subjects 48 Country South Africa and Tanzania Investigational product H1/IC31 ® Dosage H1 antigen: 50 μg IC31 adjuvant: 500 nmol KLK and 20 nmol ODN1a Dosage volume 0.5 ml Administration Two intramuscular injections, one on day 0 and one on day 56 Aurum 102 / THYB-05 The Aurum Institute and Statens Serum Institut Version 2.1 Page 4 of 48 15 February 2011 List of abbreviations GT Gamma glutamyl-transpeptidase AE Adverse event(s) Ag85B Antigen 85B AIDS Acquired Immune Deficiency Syndrome ALAT Alanine aminotransferase AM Abbreviated medical examination Aurum The Aurum Institute BCG Bacillus Calmette-Guérin CBC Complete blood count CFSE Carboxyfluorescein diacetate succinimidyl ester CPK Creatine phosphokinase CPT Cell Preparation Tube CRF Case Report Form(s) CTA Clinical Trials Application DAIDS National Institute of Health Division of AIDS DSMB Data Safety Monitoring Board EC Ethics Committee ELISA Enzyme Linked Immunosorbent Assay ELISPOT Enzyme Linked Immunosorbent Spot Assay ESAT-6 Early Secretory Antigenic Target FDA United States Food and Drug Administration FM Full medical examination FU Follow up GCP Good clinical practice(s) H1 Hybrid 1 (Ag85B-ESAT-6) H1/IC31® Ag85B-ESAT-6 + IC31 HBV Hepatitis B virus HCV Hepatitis C virus HIV Human immunodeficiency virus IB Investigator’s Brochure IC31 KLK, ODN1a ICH International Conference on Harmonisation ICS Intracellular Cytokine Staining IFNγ Interferon-gamma IgG Immunoglobulin G IgM Immunoglobulin M IM Intramuscular IRB Institutional Review Board KLK KLKLLLLLKLK LUMC Leiden University Medical Center MCC Medicines Control Council (South Africa) mL Milliliter(s) Mtb Mycobacterium tuberculosis Aurum 102 / THYB-05 The Aurum Institute and Statens Serum Institut Version 2.1 Page 5 of 48 15 February 2011 ODN1a Oligodeoxynucleotide PBMC Peripheral blood mononuclear cell(s) PCR Polymerase chain reaction PHA phytohemagglutinin PPD Purified protein derivative pys patient years QFT-GIT QuantiFERON®-TB Gold In Polymerase Chain Reaction:Article Title: Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis. Article Snippet: IGRA includes QFT-G, Article Title: Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm 3 : A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial Article Snippet: Number of subjects 48 Country South Africa and Tanzania Investigational product H1/IC31 ® Dosage H1 antigen: 50 μg IC31 adjuvant: 500 nmol KLK and 20 nmol ODN1a Dosage volume 0.5 ml Administration Two intramuscular injections, one on day 0 and one on day 56 Aurum 102 / THYB-05 The Aurum Institute and Statens Serum Institut Version 2.1 Page 4 of 48 15 February 2011 List of abbreviations GT Gamma glutamyl-transpeptidase AE Adverse event(s) Ag85B Antigen 85B AIDS Acquired Immune Deficiency Syndrome ALAT Alanine aminotransferase AM Abbreviated medical examination Aurum The Aurum Institute BCG Bacillus Calmette-Guérin CBC Complete blood count CFSE Carboxyfluorescein diacetate succinimidyl ester CPK Creatine phosphokinase CPT Cell Preparation Tube CRF Case Report Form(s) CTA Clinical Trials Application DAIDS National Institute of Health Division of AIDS DSMB Data Safety Monitoring Board EC Ethics Committee ELISA Enzyme Linked Immunosorbent Assay ELISPOT Enzyme Linked Immunosorbent Spot Assay ESAT-6 Early Secretory Antigenic Target FDA United States Food and Drug Administration FM Full medical examination FU Follow up GCP Good clinical practice(s) H1 Hybrid 1 (Ag85B-ESAT-6) H1/IC31® Ag85B-ESAT-6 + IC31 HBV Hepatitis B virus HCV Hepatitis C virus HIV Human immunodeficiency virus IB Investigator’s Brochure IC31 KLK, ODN1a ICH International Conference on Harmonisation ICS Intracellular Cytokine Staining IFNγ Interferon-gamma IgG Immunoglobulin G IgM Immunoglobulin M IM Intramuscular IRB Institutional Review Board KLK KLKLLLLLKLK LUMC Leiden University Medical Center MCC Medicines Control Council (South Africa) mL Milliliter(s) Mtb Mycobacterium tuberculosis Aurum 102 / THYB-05 The Aurum Institute and Statens Serum Institut Version 2.1 Page 5 of 48 15 February 2011 ODN1a Oligodeoxynucleotide PBMC Peripheral blood mononuclear cell(s) PCR Polymerase chain reaction PHA phytohemagglutinin PPD Purified protein derivative pys patient years QFT-GIT QuantiFERON®-TB Gold In Purification:Article Title: Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis. Article Snippet: IGRA includes QFT-G, Article Title: Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm 3 : A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial Article Snippet: Number of subjects 48 Country South Africa and Tanzania Investigational product H1/IC31 ® Dosage H1 antigen: 50 μg IC31 adjuvant: 500 nmol KLK and 20 nmol ODN1a Dosage volume 0.5 ml Administration Two intramuscular injections, one on day 0 and one on day 56 Aurum 102 / THYB-05 The Aurum Institute and Statens Serum Institut Version 2.1 Page 4 of 48 15 February 2011 List of abbreviations GT Gamma glutamyl-transpeptidase AE Adverse event(s) Ag85B Antigen 85B AIDS Acquired Immune Deficiency Syndrome ALAT Alanine aminotransferase AM Abbreviated medical examination Aurum The Aurum Institute BCG Bacillus Calmette-Guérin CBC Complete blood count CFSE Carboxyfluorescein diacetate succinimidyl ester CPK Creatine phosphokinase CPT Cell Preparation Tube CRF Case Report Form(s) CTA Clinical Trials Application DAIDS National Institute of Health Division of AIDS DSMB Data Safety Monitoring Board EC Ethics Committee ELISA Enzyme Linked Immunosorbent Assay ELISPOT Enzyme Linked Immunosorbent Spot Assay ESAT-6 Early Secretory Antigenic Target FDA United States Food and Drug Administration FM Full medical examination FU Follow up GCP Good clinical practice(s) H1 Hybrid 1 (Ag85B-ESAT-6) H1/IC31® Ag85B-ESAT-6 + IC31 HBV Hepatitis B virus HCV Hepatitis C virus HIV Human immunodeficiency virus IB Investigator’s Brochure IC31 KLK, ODN1a ICH International Conference on Harmonisation ICS Intracellular Cytokine Staining IFNγ Interferon-gamma IgG Immunoglobulin G IgM Immunoglobulin M IM Intramuscular IRB Institutional Review Board KLK KLKLLLLLKLK LUMC Leiden University Medical Center MCC Medicines Control Council (South Africa) mL Milliliter(s) Mtb Mycobacterium tuberculosis Aurum 102 / THYB-05 The Aurum Institute and Statens Serum Institut Version 2.1 Page 5 of 48 15 February 2011 ODN1a Oligodeoxynucleotide PBMC Peripheral blood mononuclear cell(s) PCR Polymerase chain reaction PHA phytohemagglutinin PPD Purified protein derivative pys patient years QFT-GIT QuantiFERON®-TB Gold In |
